載入...
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib has demonstrated dramatic clinical efficacy in non-small cell lung cancer (NSCLC) patients. However, its therapeutic efficacy is ultimately limited by the development of acquired drug resistance. The aim of this study...
Na minha lista:
| 發表在: | Toxicol Appl Pharmacol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5643250/ https://ncbi.nlm.nih.gov/pubmed/28942004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.taap.2017.09.017 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|